2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2564

Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus
Abstract Number: 2565

Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Abstract Number: 2566

Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE
Abstract Number: 2567

Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates
Abstract Number: 2568

Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study
Abstract Number: 2569

Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review
Abstract Number: 2570

Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis
Abstract Number: 2571

Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus
Abstract Number: 2572

Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status
Abstract Number: 2573

Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels
Abstract Number: 2574

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters
Abstract Number: 2575

Electronic Monitoring of Medication Adherence in Young Adults with Childhood-Onset Systemic Lupus Erythematosus over 12 Weeks
Abstract Number: 2576

Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE
Abstract Number: 2577

SLE Disease Activity May Be Associated with Choroidal Thickness
Abstract Number: 2578

Effect of Omega-3 Fatty Acids on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].